Papain-like lysosomal cysteine proteases and their inhibitors: drug discovery _targets?
- PMID: 14587279
- DOI: 10.1042/bss0700015
Papain-like lysosomal cysteine proteases and their inhibitors: drug discovery _targets?
Abstract
Papain-like lysosomal cysteine proteases are processive and digestive enzymes that are expressed in organisms from bacteria to humans. Increasing knowledge about the physiological and pathological roles of cysteine proteases is bringing them into the focus of drug discovery research. These proteases have rather short active-site clefts, comprising three well defined substrate-binding subsites (S2, S1 and S1') and additional broad binding areas (S4, S3, S2' and S3'). The geometry of the active site distinguishes cysteine proteases from other protease classes, such as serine and aspartic proteases, which have six and eight substrate-binding sites respectively. Exopeptidases (cathepsins B, C, H and X), in contrast with endopeptidases (such as cathepsins L, S, V and F), possess structural features that facilitate the binding of N- and C-terminal groups of substrates into the active-site cleft. Other than a clear preference for free chain termini in the case of exopeptidases, the substrate-binding sites exhibit no strict specificities. Instead, their subsite preferences arise more from the specific exclusion of substrate types. This presents a challenge for the design of inhibitors to _target a specific cathepsin: only the cumulative effect of an assembly of inhibitor fragments will bring the desired result.
Similar articles
-
Lysosomal cysteine proteases (cathepsins): promising drug _targets.Acta Crystallogr D Biol Crystallogr. 2003 Feb;59(Pt 2):203-13. doi: 10.1107/s0907444902021479. Epub 2003 Jan 23. Acta Crystallogr D Biol Crystallogr. 2003. PMID: 12554931 Review.
-
Structural basis of inhibition of cysteine proteases by E-64 and its derivatives.Biopolymers. 1999;51(1):99-107. doi: 10.1002/(SICI)1097-0282(1999)51:1<99::AID-BIP11>3.0.CO;2-R. Biopolymers. 1999. PMID: 10380357
-
New peptidic cysteine protease inhibitors derived from the electrophilic alpha-amino acid aziridine-2,3-dicarboxylic acid.J Med Chem. 1999 Feb 25;42(4):560-72. doi: 10.1021/jm981061z. J Med Chem. 1999. PMID: 10052963
-
Structural and functional aspects of papain-like cysteine proteinases and their protein inhibitors.Biol Chem. 1997 Mar-Apr;378(3-4):141-50. Biol Chem. 1997. PMID: 9165064 Review.
-
Binding modes of a new epoxysuccinyl-peptide inhibitor of cysteine proteases. Where and how do cysteine proteases express their selectivity?Biochim Biophys Acta. 1999 May 18;1431(2):290-305. doi: 10.1016/s0167-4838(99)00053-9. Biochim Biophys Acta. 1999. PMID: 10350606
Cited by
-
Cathepsin K null mice show reduced adiposity during the rapid accumulation of fat stores.PLoS One. 2007 Aug 1;2(8):e683. doi: 10.1371/journal.pone.0000683. PLoS One. 2007. PMID: 17668061 Free PMC article.
-
Identification, mRNA expression profiling and activity characterization of cathepsin L from red drum (Sciaenops ocellatus).Fish Physiol Biochem. 2015 Dec;41(6):1463-73. doi: 10.1007/s10695-015-0099-9. Epub 2015 Jul 12. Fish Physiol Biochem. 2015. PMID: 26164862
-
Cysteine cathepsins: from structure, function and regulation to new frontiers.Biochim Biophys Acta. 2012 Jan;1824(1):68-88. doi: 10.1016/j.bbapap.2011.10.002. Epub 2011 Oct 12. Biochim Biophys Acta. 2012. PMID: 22024571 Free PMC article. Review.
-
Structure determinants defining the specificity of papain-like cysteine proteases.Comput Struct Biotechnol J. 2022 Nov 24;20:6552-6569. doi: 10.1016/j.csbj.2022.11.040. eCollection 2022. Comput Struct Biotechnol J. 2022. PMID: 36467578 Free PMC article. Review.
-
Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer's disease ameliorates amyloid pathologies and memory deficits.Brain. 2011 Jan;134(Pt 1):258-77. doi: 10.1093/brain/awq341. Brain. 2011. PMID: 21186265 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources